Current agents that have been studied for use in ROP include bevacizumab, ranibizumab, aflibercept, conbercept, and pegaptanib (a pegylated anti-VEGF aptamer) [126,127,128,129]. Here, VEGFA is linked to retinopathy of prematurity.